Sellas’ Experimental Drug SLS009 Appears To Be Leading The CDK9 Race, Says Alliance Global – Analyst Sees About 200% Upside Potential
Sellas Life Sciences (SLS) shares rose 5.4% after Alliance Global analyst James Molloy highlighted the potential of its experimental drug SLS009 for treating acute myeloid leukemia. Molloy raised the price target to $35, suggesting 200% upside. SLS009 is in a Phase 2 trial with topline data expected in Q4 2026. Sellas reported a Q2 net loss of $9.6 million, wider than estimates, with R&D costs increasing. Cash reserves totaled $138.3 million.
How this was made
The 30-second read
Why it matters
Analyst upgrade and trial enrollment suggest near‑term upside, but clinical risk remains.
Market read
New analyst target and trial progress could trigger buying activity in SLS and related biotech stocks.
What to watch
Cash runway of $138M may limit further trial funding if results disappoint.
Background
Sellas Life Sciences is a small‑cap biotech developing CDK9 inhibitor SLS009 for AML and PDAC.
Ticker impact
Analyst James Molloy raised SLS price target to $35 from $25 and maintained a Buy rating, citing SLS009 as leading CDK9 inhibitor trial.
Potential short-term rally of 5‑10% as investors digest the upgraded target.
Target raise is new information; market has already moved 5.4% higher, indicating immediate impact.
Market effects
Highlights competitive edge of CDK9 inhibitors, may benefit biotech sector peers.
US biotech investors likely to re‑price similar small‑cap trials.
Limited to biotech investors; no broad market effect.
Counterpoint
Target raise may be premature without Phase 2 data; risk of overvaluation.
Key entities
- companySellas Life Sciences
Biotech firm developing SLS009.
- analystJames Molloy
Equity analyst who raised the price target.
